Pacira BioSciences Inc. Common Stock (PCRX)
Stock · NASDAQ · Health Care
$36.34as of 10/16/2026
Price chart
Active signals
PCRX Signal Track Record
How signals performed across all stocks →What PCRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -2.4% | 47% | October 8, 2026 |
| Bollinger Band Breakdown | 25 | -0.3% | 48% | August 12, 2026 |
| Bollinger Band Breakout | 20 | -3.5% | 40% | October 8, 2026 |
| 200-Day Moving Average TouchActive now | 18 | -3.6% | 44% | September 15, 2026 |
| Any 20-session window (baseline) | -1.6% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the manage…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 825
- Website
- www.pacira.com/
Fundamentals
- 1-day range
- $36.32$36.35
- Market cap
- $1.02B
- P/E (trailing)
- 98.88
- P/E (forward)
- 10.51
- EPS (trailing)
- $0.35
- Dividend yield
- —
- Beta
- 0.32
- Avg. volume
- 1.10M
How Pacira BioSciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Pacira BioSciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PCRXPacira BioSciences Inc. Common Stock$36.34▲ 0.03%Market cap $1.02BP/E 98.88$18.8$36.46
- OLMAOlema Pharmaceuticals Inc. Common Stock$6.58▼ 4.22%Market cap $1.03BP/E —$6.61$36.26
- ANLAdlai Nortye Ltd. American Depositary Shares$11.03▼ 8.77%Market cap $1.01BP/E —$0.879$17.25
- GERNGeron Corporation Common Stock$1.17▼ 4.88%Market cap $1.01BP/E —$1.04$2.01
- LXRXLexicon Pharmaceuticals Inc. Common Stock$1.52▼ 7.88%Market cap $1.05BP/E —$1.1$2.68
- AVTXAvalo Therapeutics Inc. Common Stock$11.27▼ 6.16%Market cap $989.29MP/E —$12.51$24.27
- OPKOPKO Health Inc. Common Stock$1.53▼ 4.97%Market cap $985.15MP/E —$0.98$1.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PCRX Pacira BioSciences Inc. Common Stock | $1.02B | 98.88 | $36.34 | ▲ 0.03% | $18.8$36.46 |
| OLMA Olema Pharmaceuticals Inc. Common Stock | $1.03B | — | $6.58 | ▼ 4.22% | $6.61$36.26 |
| ANL Adlai Nortye Ltd. American Depositary Shares | $1.01B | — | $11.03 | ▼ 8.77% | $0.879$17.25 |
| GERN Geron Corporation Common Stock | $1.01B | — | $1.17 | ▼ 4.88% | $1.04$2.01 |
| LXRX Lexicon Pharmaceuticals Inc. Common Stock | $1.05B | — | $1.52 | ▼ 7.88% | $1.1$2.68 |
| AVTX Avalo Therapeutics Inc. Common Stock | $989.29M | — | $11.27 | ▼ 6.16% | $12.51$24.27 |
| OPK OPKO Health Inc. Common Stock | $985.15M | — | $1.53 | ▼ 4.97% | $0.98$1.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell RightsYahoo · 10/10/2026
- Pacira Biosciences' Acquisition by Viatris Unlikely to See Superior Bid, RBC SaysYahoo · 10/9/2026
- Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioYahoo · 10/9/2026
- Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5Benzinga · 10/9/2026
- RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5Benzinga · 10/9/2026
- This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For FridayBenzinga · 10/9/2026
- CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For FridayBenzinga · 10/9/2026
- HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5Benzinga · 10/9/2026
Insider Activity
Insider Actions →- Lauren Riker · October 8, 2026 · Option Exercise6.0K @ $32.35
- Lauren Riker · October 8, 2026 · Sale6.0K @ $36.32
- Jonathan Slonin · August 17, 2026 · Sale3.0K @ $23.23
- Lauren Riker · June 11, 2026 · Sale6.1K @ $23.5
- Samit Hirawat · June 10, 2026 · Grant6.4K
- Michael J. Yang · June 10, 2026 · Grant6.4K
- Marcelo Bigal · June 10, 2026 · Grant10.9K
- Marcelo Bigal · June 10, 2026 · Grant6.4K
- Mark Froimson · June 10, 2026 · Grant10.9K
- Samit Hirawat · June 10, 2026 · Grant10.9K
- Christopher Christie · June 10, 2026 · Grant10.9K
- Christopher Christie · June 10, 2026 · Grant6.4K
- Alethia Young · June 10, 2026 · Grant10.9K
- Alethia Young · June 10, 2026 · Grant6.4K
- Michael J. Yang · June 10, 2026 · Grant10.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 40.23M
- Total value held
- $886.84M
- Institutional holders
- 232
- Unknown6.74M
- Unknown2.78M
- Unknown2.06M
- Unknown1.98M
- Unknown1.92M
- Unknown1.83M
- Unknown1.78M
- Unknown1.57M
- Unknown1.39M
- Unknown1.14M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.